Combigene AB — Investor Relations & Filings

CombiGene AB is a gene therapy company focused on developing treatments for severe, life-altering diseases with significant unmet medical needs, particularly neurological disorders. The company's lead project, CG01, is an adeno-associated virus (AAV)-based gene therapy candidate designed for the treatment of drug-resistant focal epilepsy. In 2021, CG01 was exclusively licensed in a global agreement to Spark Therapeutics. CombiGene is also developing a gene therapy for chronic pain through a collaboration with the company Zyneyro. The company's mission is to provide patients with the prospect of a better life through novel gene therapies where current treatment methods are inadequate.